Navigation Links
Diabetes drug kills cancer stem cells in combination treatment in mice
Date:9/14/2009

BOSTON, Mass. (September 14, 2009) -- In a one-two punch, a familiar diabetes drug reduced tumors faster and prolonged remission in mice longer than chemotherapy alone, apparently by targeting cancer stem cells, report Harvard Medical School researchers in the Sept. 14 advance online Cancer Research.

"We have found a compound selective for cancer stem cells," said senior author Kevin Struhl, the David Wesley Gaiser professor of biological chemistry and molecular pharmacology at HMS. "What's different is that ours is a first-line diabetes drug."

The findings add to a growing body of preliminary evidence in cells, mice, and people that metformin may improve breast cancer outcomes in people. In this study, the diabetes drug seemed to work independently of its ability to improve insulin sensitivity and lower blood sugar and insulin levels, all of which are also associated with better breast cancer outcomes.

The results fit within the cancer stem cell hypothesis, an intensely studied idea that a small subset of cancer cells has a special power to initiate tumors, fuel tumor growth, and promote recurrence of cancer. Cancer stem cells appear to resist conventional chemotherapies, which kill the bulk of the tumor.

"There is a big desire to find drugs specific to cancer stem cells," Struhl says. "The cancer stem cell hypothesis says you cannot cure cancer unless you also get rid of the cancer stem cells. From a purely practical point of view, this could be tested in humans. It's already used as a first-line diabetes drug."

The possible usefulness of a diabetes drug against cancer lends credence to an emerging idea that, in the vast and complex alphabet soup of molecular interactions within cells, relatively few biological pathways will turn out to be most important for many different diseases, Struhl suggested.

In experiments led by postdoctoral fellows Heather Hirsch and Dimitrios Iliopoulos, the combinatio
'/>"/>

Contact: Carol Cruzan Morton
carol_morton@hms.harvard.edu
617-432-3121
Harvard Medical School
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Scientists show that mitochondrial DNA variants are linked to risk factors for type 2 diabetes
2. Gender, coupled with diabetes, affects vascular disease development
3. Breakthrough research identifies how cells from pigs may cure diabetes
4. Botched production of insulin molecule may lead to diabetes
5. Joslin researchers uncover potential role of leptin in diabetes
6. Insulins brain impact links drugs and diabetes
7. Exercise improves thinking, reduces diabetes risk in overweight children
8. UVa Health System team uncovers genes role in type 1 diabetes
9. Childrens Hospital studying drug with the potential to prevent/delay onset of type 1 diabetes
10. JDRF awards University of Copenhagen professor with grant to conduct innovative diabetes research
11. Cancer and arthritis therapy may be promising treatment for diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , Dec. 15, 2014 Research and Markets ... addition of the "Samsung Galaxy S5 - ... report to their offering. ... totally different sensing technology than the iPhone 5S, ... sensor in its product. The Galaxy ...
(Date:12/17/2014)... YORK , Dec. 15, 2014  HITLAB ... Good Clinical Practices (GCP) audit to confirm its ... (FDA) regulations. This accomplishment enables HITLAB to conduct ... utilizing the highest principles for patient safety and ... improve global healthcare access, quality, and delivery with ...
(Date:12/17/2014)... 2014 Research and Markets ( ... "Global Chemical Sensor Market 2015-2019" report ... http://photos.prnewswire.com/prnh/20130307/600769 One major trend upcoming ... medical sensors in biomedical applications. Chemical sensors help ... correct diagnosis during surgical procedures. The Global Chemical ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... depression and other mood disorders may lie in a ... inhibit other cells) shown to contribute to symptoms like ... in a new study in the Journal of ... from depression and other mood disorders often react to ...
... Bethesda, MD -- According to new research published in ... zinc levels does not directly harm the blood vessel cells. ... which then circulates in the blood and causes harmful blood ... of zinc prevent the creation of this compound, but it ...
... was right when she warned you that loud music could ... gets damaged and how. In a research report published in ... , scientists describe exactly what type of damage noise ... compound that may prevent noise-related damage. ...
Cached Biology News:Penn study: Shutting off neurons helps bullied mice overcome symptoms of depression 2Potential diagnostic marker for zinc status offers insights into the effects of zinc deficiency 2Now hear this: Scientists discover compound to prevent noise-related hearing loss 2
(Date:12/24/2014)... 24, 2014  United Therapeutics Corporation (NASDAQ: ... (NYSE: MDT ) has submitted a ... Drug Administration (FDA) for the use of Medtronic,s ... (including a newly developed catheter) for use with ... intravenously to patients with pulmonary arterial hypertension.   ...
(Date:12/24/2014)... GMO corn cases filed across the ... in the process of being consolidated in a Kansas ... In Re: Syngenta AG MIR 162 Corn Litigation, MDL ... District of Kansas. , Management of the Syngenta GMO ... U.S. District Judge John W. Lungstrum.* , As a ...
(Date:12/24/2014)... The report provides basic ... definition, classification, application and industry overview. This ... and product cost structure. Production is separated ... also covers upstream raw materials, equipment, downstream ... and proposals. In the end, the export ...
(Date:12/24/2014)... Dec. 23, 2014 Vermillion, Inc. (Nasdaq: ... gynecologic disease, announced today that investors including Oracle ... Fund LLC and several Vermillion directors have agreed ... of Vermillion,s common stock and warrants to purchase ... private placement.  Under the terms ...
Breaking Biology Technology:United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5
... The following news advisory is being issued by MichBio: ... the meeting an important development for Michigan biosciences will ... for the bioscience industry When: Wednesday, May ... Dinner , 7:00 p.m. Meeting Purpose: The ...
... Programs; Agreement Underscores SAFC,s Commitment to Japan ... SAFC Hitech (R), a business segment within ... SIAL ), today underlined its commitment to Japan,s microelectronics industry ... industrial and medical gas producer, Air Water Inc ...
... acceptable primary endpoint, for a regulatory ... /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI ... agreement with the U.S. Food and Drug Administration (FDA) ... trial of OGX-011, its lead product candidate targeting castrate ...
Cached Biology Technology:Key Industry-Relevant Development to be Announced at MichBio's 2009 Annual Meeting on May 6 2SAFC Hitech & Air Water Inc. Extend High-End Materials Research Services Collaboration to Support Japan Chip Industry 2SAFC Hitech & Air Water Inc. Extend High-End Materials Research Services Collaboration to Support Japan Chip Industry 3SAFC Hitech & Air Water Inc. Extend High-End Materials Research Services Collaboration to Support Japan Chip Industry 4SAFC Hitech & Air Water Inc. Extend High-End Materials Research Services Collaboration to Support Japan Chip Industry 5OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer 2OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer 3OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer 4OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer 5OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer 6
...
... Peptide-Protein Conjugation, ... Bridges, Complex Peptides/Peptidomimetics, Special ... Phosphorylated/Biotinylated Structures, Peptide labeling AMC, ... -99%, fitting your needs, Chromogenic/Flurogenic ...
4-Hydroxy-3-nitrophenylacetyl hapten is conjugated to KLH (Keyhole Limpet Hemocyanin) lysine through amide bonds....
...
Biology Products: